Cargando…
Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials
BACKGROUND AND OBJECTIVE: Tacrolimus has been widely used in recent years for treating allergic conjunctivitis, but there is currently no available meta-analysis regarding its therapeutic efficacy. This study systematically evaluated the effectiveness of tacrolimus in the treatment of allergic conju...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047954/ https://www.ncbi.nlm.nih.gov/pubmed/33144336 http://dx.doi.org/10.1136/ejhpharm-2020-002447 |
_version_ | 1784695835161788416 |
---|---|
author | Zhao, Min He, Fazhong Yang, Yang Lin, Weijie Qiu, Wentao Meng, Qian Zhang, Jianping Zhou, Zhiling |
author_facet | Zhao, Min He, Fazhong Yang, Yang Lin, Weijie Qiu, Wentao Meng, Qian Zhang, Jianping Zhou, Zhiling |
author_sort | Zhao, Min |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Tacrolimus has been widely used in recent years for treating allergic conjunctivitis, but there is currently no available meta-analysis regarding its therapeutic efficacy. This study systematically evaluated the effectiveness of tacrolimus in the treatment of allergic conjunctivitis. METHODS: Data obtained from literature searches of the PubMed, Cochrane Library, Embase, CNKI, and Wanfang databases were retrieved by combining medical subject words and free words. Literature was selected on the basis of established inclusion and exclusion criteria, and the extracted data were evaluated for risk of bias using RevMan 5.3 for meta-analysis. RESULTS: A total of 177 articles were retrieved, of which 5 articles were eventually selected, all of which involved tacrolimus treatment for vernal keratoconjunctivitis. A total of 203 samples were analysed. Results of the meta-analysis showed that the tacrolimus treatment group had significantly lower ocular objective sign scores (SMD −1.39, 95% CI −2.50 to −0.27; p<0.05) and had a significantly lower subjective symptom evaluation score (SMD −0.92, 95% CI −1.59 to −0.24; p<0.05) than the control group. CONCLUSION: Current evidence shows that tacrolimus is effective in treating vernal keratoconjunctivitis. |
format | Online Article Text |
id | pubmed-9047954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-90479542022-05-11 Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials Zhao, Min He, Fazhong Yang, Yang Lin, Weijie Qiu, Wentao Meng, Qian Zhang, Jianping Zhou, Zhiling Eur J Hosp Pharm Systematic Review BACKGROUND AND OBJECTIVE: Tacrolimus has been widely used in recent years for treating allergic conjunctivitis, but there is currently no available meta-analysis regarding its therapeutic efficacy. This study systematically evaluated the effectiveness of tacrolimus in the treatment of allergic conjunctivitis. METHODS: Data obtained from literature searches of the PubMed, Cochrane Library, Embase, CNKI, and Wanfang databases were retrieved by combining medical subject words and free words. Literature was selected on the basis of established inclusion and exclusion criteria, and the extracted data were evaluated for risk of bias using RevMan 5.3 for meta-analysis. RESULTS: A total of 177 articles were retrieved, of which 5 articles were eventually selected, all of which involved tacrolimus treatment for vernal keratoconjunctivitis. A total of 203 samples were analysed. Results of the meta-analysis showed that the tacrolimus treatment group had significantly lower ocular objective sign scores (SMD −1.39, 95% CI −2.50 to −0.27; p<0.05) and had a significantly lower subjective symptom evaluation score (SMD −0.92, 95% CI −1.59 to −0.24; p<0.05) than the control group. CONCLUSION: Current evidence shows that tacrolimus is effective in treating vernal keratoconjunctivitis. BMJ Publishing Group 2022-05 2020-11-03 /pmc/articles/PMC9047954/ /pubmed/33144336 http://dx.doi.org/10.1136/ejhpharm-2020-002447 Text en © European Association of Hospital Pharmacists 2022. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Systematic Review Zhao, Min He, Fazhong Yang, Yang Lin, Weijie Qiu, Wentao Meng, Qian Zhang, Jianping Zhou, Zhiling Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials |
title | Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials |
title_full | Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials |
title_fullStr | Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials |
title_full_unstemmed | Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials |
title_short | Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials |
title_sort | therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047954/ https://www.ncbi.nlm.nih.gov/pubmed/33144336 http://dx.doi.org/10.1136/ejhpharm-2020-002447 |
work_keys_str_mv | AT zhaomin therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials AT hefazhong therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials AT yangyang therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials AT linweijie therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials AT qiuwentao therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials AT mengqian therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials AT zhangjianping therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials AT zhouzhiling therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials |